y***q
发帖数: 4147 | 1 基本面有人FA过了，现在就是找入点了。
我最近看股票看不准的，你帮着把把关。 | a****g
发帖数: 8131 | | y***q
发帖数: 4147 | 3 你经常不在。牛jj是小孩子，一叫就到
【在 a****g 的大作中提到】
: 妹，为什么不叫我看？
| b**********k
发帖数: 1262 | 4 看你打算拿多久了.....
我不知道 你问googer和主席吧， 他们两个都很厉害
【在 y***q 的大作中提到】
: 你经常不在。牛jj是小孩子，一叫就到
| M***y
发帖数: 1594 | | y***q
发帖数: 4147 | 6 我也看不懂，觉得不是好入点
【在 b**********k 的大作中提到】
: 看你打算拿多久了.....
: 我不知道 你问googer和主席吧， 他们两个都很厉害
| D******9
发帖数: 2665 | 7 They have only one drug, and the revenue is only 8 million.
Here is the news:
InterMune reported product revenue in the fourth quarter of 2011 of $7.8
million, consisting of $2.7 million from sales of Esbriet in Europe, and
Actimmune® (gamma interferon-1b) revenue of approximately $5.2 million.
Product sales in the fourth quarter 2010 consisted solely of $4.9 million
of Actimmune revenue, as the initial commercial launch of Esbriet was in
Germany in September 2011.
InterMune reported a net loss for the fourth quarter of 2011 of $44.5
million, or $0.69 per share, compared with net income of $206.1 million, or
$3.34 per diluted share, in the fourth quarter of 2010. Net income in the
fourth quarter of 2010 was driven by the sale of InterMune's danoprevir
asset to Roche and the accelerated recognition of deferred revenue in
connection with the termination of InterMune's 2006 collaboration agreement
with Roche. |
|
